drugset / Trial / NCT05844982
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Phase 3
Recruiting
600 enrolled
Jaeb Center for Health Research
Alimera Sciences · collabGenentech, Inc. · collabNational Eye Institute (NEI) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Timeline
- Start
- 2023-11-21
- Primary completion
- 2029-12-26
- Completion
- 2029-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Faricimab | Monoclonal antibody | 6 mg | Intravitreal |
| Comparator | fluocinolone acetonide | Small molecule | 0.19 mg | Intravitreal |